Benefit and Risk of Prolonged DAPT After Coronary Stenting in Women: Results From the DAPT Study. (August 2018)

• Record Type: Journal Article
• Authors: Berry, Natalia C.; Kereiakes, Dean J.; Yeh, Robert W.; Steg, P. Gabriel; Cutlip, Donald E.; Jacobs, Alice K.; Abbott, J. Dawn; Hsieh, Wen-Hua; Massaro, Joseph M.; Mauri, Laura
• Is Part Of: Circulation. Volume 11:Number 8(2018)
• Publication Date: 2018-08
• Subjects: acute coronary syndrome -- diabetes mellitus -- myocardial infarction -- stents -- thienopyridine; Cardiovascular system -- Surgery -- Periodicals; Cardiovascular system -- Diseases -- Treatment -- Periodicals; 616.105
• DOI: 10.1161/CIRCINTERVENTIONS.117.005308
• Languages: English
• ISSNs: 1941-7640

Abstract

Abstract : Background: Women may derive differential benefit from prolonged DAPT (dual antiplatelet therapy) after coronary stenting than men. We assessed whether the risks/benefits of prolonged DAPT differ between women and men. Methods and Results: The DAPT study was a randomized double-blind, placebo-controlled trial comparing continued thienopyridine versus placebo beyond 12 months after coronary stenting. We compared rates of myocardial infarction, stent thrombosis, major adverse cardiovascular and cerebrovascular events, and bleeding by sex and randomized treatment. Of 11 648 patients, women (N=2925) were older, with higher prevalence of diabetes mellitus and lower rates of acute coronary syndrome than men. At 12 to 30 months, women had similar adjusted ischemic and bleeding events as men. The effects of continued thienopyridine therapy did not differ significantly by sex for stent thrombosis (women: hazard ratio [HR], 0.54; 95% confidence interval [CI], 0.22–1.36; men: HR, 0.26; 95% CI, 0.15–0.44; interaction P =0.17), myocardial infarction (women: HR, 0.75; 95% CI, 0.50–1.14; men: HR, 0.46; 95% CI, 0.36–0.60; interaction P =0.052), major adverse cardiovascular and cerebrovascular events (women: HR, 0.87; 95% CI, 0.62–1.22; men: HR, 0.70; 95% CI, 0.58–0.85; interaction P =0.26), and bleeding (women: HR, 1.45; 95% CI, 0.88–2.40; men: HR, 1.78; 95% CI, 1.28–2.49; interaction P =0.50). Conclusions: Women had similar late risks of ischemia and bleeding as men after coronary stent procedures. Clinical Trial Registration: URL:https://www.clinicaltrials.gov . Unique identifier: NCT00977938.